Researchers have identified the cause of chronic, and currently untreatable, pain in those with amputations and severe nerve damage, as well as a potential treatment which relies on engineering instead of drugs.
An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline (GSK).
Lawrence King (Department of Sociology) and Piotr Ozieranski (University of Bath) discuss how EU member states use complex policy instruments to determine how much they are willing to pay the pharmaceutical industry for its products.
At a workshop next Monday (25 April 2016), Dr Ina Linge and Professor David Spiegelhalter will lead a discussion about the historical documentation of human sexuality – from questionnaires to the diaries of cross-dressers. The event (part of a series titled Sex in Six Objects) is open to people aged 16 to 25.
Graham Ladds, lecturer in pharmacology, discusses the controversy around a group of drugs used to treat Type 2 diabetes.
Scientists have found that some drugs from a group of anti-diabetic treatments may, in certain circumstances, act on glucagon receptors in the body, meaning that they could also potentially enable the release of sugar into the bloodstream.
A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has today become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.
In a talk on 17 February, Margaret Carlyle, a researcher in the Department of History and Philosophy of Science, will explore the fascinating (often gruesome) development in 18th-century Paris of anatomical models and introduce her audience to a remarkable woman who made her name in a field dominated by men.
A new therapy for peanut allergy has been successful in the majority of the 99 children who took part in a clinical trial.
From the elixirs of legend to transmutation of base metals into gold, medieval medical practice and social mobility were steeped in alchemy.